Furthermore, survival analysis of AML patients included in The Cancer Genome Atlas (TCGA) dataset showed that both NRF2 and GPX4 expression were significantly associated with poor overall survival (OS) (Fig. 2e and Figure S3a-b), indicating that their increased expression is associated with poor prognosis in AML. Here, GPX4 is linked to acute myeloid leukemia.